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ABSTRACT
Display of heterologous proteins on the surface of Saccharomyces cerevisiae is increasingly
being exploited for directed evolution because of straightforward cell screens. However, yeast
post-translationally modifies proteins in ways that must be factored into library engineering and
refinement.

Here, we express the extracellular immunoglobulin domain of an ubiquitous

mammalian membrane protein, CD47, which is implicated in cancer, immunocompatibility, and
motility. CD47 has multiple sites of glycosylation and a core disulfide bond. We assess the
effects of both of these post-translational modifications on expression and antibody binding.
CD47’s extracellular domain is fused to the yeast mating protein Aga2p on the cell wall, and the
resulting fusion protein binds several key antibodies, including a conformation-sensitive
antibody. Site-by-site mutagenesis of CD47’s five N-linked glycosylation sites progressively
decreases expression levels on yeast, but folding appears stable. Cysteine mutations disrupt the
expected core disulfide, and also decrease protein expression levels, though not to the extent seen
with complete deglycosylation. However, with the core disulfide mutants, antibody binding
proves to be lower than expression levels might indicate and glycosylation is clearly reduced
compared to wild-type. The results indicate that glycosylation regulates heterologous display on
yeast more than core disulfides do and thus suggest bounds on directed evolution by posttranslational processing. (201 words)

Keywords: yeast display, glycosylation, disulfide, immunoglobulin, CD47

3
INTRODUCTION
Yeast display of recombinant proteins is an increasingly popular technique for the study of
structure-function relationships (Boder and Wittrup, 2000). A large part of this appeal is the
potential for rapid screening of a library using techniques such as flow cytometry or magnetically
assisted cell sorting (Yeung and Wittrup, 2002; Siegel et al., 2004; Feldhaus and Siegel, 2004).
However, a number of questions arise with the yeast display of mammalian proteins. The extent
and type of glycosylation, for example, is one particularly well-recognized difference between
these single cell eukaryotes and higher organisms (Gerngross, 2004) and recognition of the
problems that variant glycosylation can pose prompted a humanization of the glycoprocessing in
Pichia pastoris (Hamilton et al., 2003). In the context of directed evolution of mammalian
proteins displayed on Saccharomyces cerevisae, it is especially important to understand posttranslational bounds to functional expression.
One of the largest families of cell surface proteins is the immunoglobulin (Ig)
superfamily, whose members share an Ig-fold and several other structural features. They tend to
be N-glycosylated. Beyond protecting partially-folded proteins from aggregation, Nglycosylation in cell surface proteins has been implicated in providing protection against
hydrolysis, ligand channeling to increase affinity, scaffold formation for an ensemble of
interacting proteins or even providing a handle whereby a receptor may discriminate ligand from
non-ligand (Rudd et al., 1999; 2004). At least one disulfide bond is found in the vast majority of
the Ig domains of these proteins, and, based on many available structures, the disulfide is
invariably buried in the core near the center of the structure. Ig domains also occur in a large
number of intracellular proteins (eg. titin, filamin), but these intracellular Ig proteins lack the
core disulfides. Disulfides are therefore not needed in general for folding of an Ig domain.
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Whether S-S bond formation and N-linked glycosylation are coupled is an interesting, if
difficult, question. Some hints are available in the literature: glycosylation was found to assist
folding of the -subunit of human chorionic gonadotrophin in CHO cells by enabling disulfide
bond formation (Feng et al., 1995). The adenosine receptor is N-glycosylated in mammalian
systems and has a disulfide bond, but, when expressed in yeast, the human adenosine receptor
was not N-glycosylated, although it did contain the disulfide bond and was functional (Butz et al,
2003). The mouse substance P receptor was not N-glycosylated either, but it was retained
intracellularly and was found to lack a disulfide bond (Niebauer et al., 2004). It must be
emphasized that the disulfide bond in this case was not a core disulfide, as it is in the many Ig
domains.
CD47 or Integrin Associated Protein (IAP) is a prototypical membrane glycoprotein that
is ubiquitous in multicellular eukaryotes (Brown and Frazier, 2001) and possesses a single,
extracellular Ig domain. Some of the earliest reports showed CD47 to be over-expressed in
ovarian carcinomas (Campbell et al., 1992), making it a target for in vivo imaging and drug
delivery (Merdan et al., 2003). Closely related if not identical forms of CD47 were also shown
to regulate cytoskeletal architecture and motility in concert with integrins (Brown and Frazier,
2001). More recently, CD47 has been postulated to mediate apoptosis of leukemic cells in mice
(Kikuchi et al., 2004) and chronic lymphocytic leukemia B-cells in humans (Mateo et al., 2002).
It is also reported to have a role on red blood cells as a ‘marker of self’ (in mice) that inhibits
phagocytosis (Oldenborg et al., 2000). Glycosylation has been implicated as a determinant of
binding specificity in at least one binding partner of CD47 (van den Nieuwenhof et al, 2001;
Ogura et al., 2004), but analogous information is lacking for CD47 itself. Using yeast surface
display as a platform, we describe here the roles that variant glycosylation and disulfide bond
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formation play in determining surface expression levels and conformation of CD47’s Ig domain
(IgCD47).

MATERIALS & METHODS
Plasmids
The extracellular domain of human CD47 (amino acids 1-122 ; IgCD47) was cloned from a
mammalian expression vector, pIAP45. We added a c-myc epitope (EQKLISEEDL) and the
synthetic pre signal peptide (Arnold et al., 1998) (N-terminal to epitope) to the N-terminus and
the FLAG epitope (DYKDDDDK) to the C-terminus of IgCD47. This fragment was cloned into
pCT4, a yeast display vector (Boder et al., in press), using the restriction sites for Aat II and Nhe
I introduced into the 5’ and 3’ primers. The epitope-flanked IgCD47 was linked at its carboxy
terminus to Aga2p with an intervening (Gly4Ser)3 linker to yield the sequence c-myc-IgCD47FLAG-linker-Aga2p.

The sequence, DDDDK, also constitutes an enterokinase (EK)

recognition site, enabling the use of enterokinase to cleave IgCD47from Aga2p. Plasmid
manipulations were performed in DH5

Escherichia coli (Invitrogen Corporation, Carlsbad,

California). All enzymes and reagents used for cloning were obtained from New England
Biolabs (Beverly, MA).

Sequencing was done at the DNA Sequencing Facility of the

Biomedical Core Facilities, Department of Genetics, University of Pennsylvania.

Site-directed Mutagenesis
Mutagenesis essentially followed the Quikchange protocol outlined by Stratagene (Stratagene
Corporation, La Jolla, California). After PCR with the template plasmid and two complementary
mutagenic primers, the restriction enzyme Dpn I was used to digest template (unmutated). A
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portion of the PCR product was then transformed into DH5 (Invitrogen). Several single
colonies were screened for the desired mutation by sequencing.

Transformation and induction of protein expression in yeast
The S. cerevisiae strain, EBY 100, described elsewhere (Boder and Wittrup, 2000), was used for
display. Yeast were transformed using the lithium acetate method (Gietz and Wood, 2004) and
plated onto selective medium (SD with Casamino acids, SDCAA). Expression under the control
of the GAL1 promoter is induced by galactose. Single colonies were then inoculated into liquid
SDCAA and allowed to grow to an optical density between 1 and 2, following which they were
switched to liquid SGCAA (where galactose replaces dextrose) supplemented with 10% glycerol
and incubated overnight at 30º. Omitting the glycerol had no discernible effect on the expression
of IgCD47 (data not shown).

Immunofluorescence, microscopy and flow cytometry
Indirect immunofluorescent staining was used with a secondary polyclonal goat anti-mouse
antibody conjugated to R-phycoerythrin (Sigma, St Louis, MO). The sources of the mAbs used
in this study are as follows: B6H12 was from BD Biosciences Pharmingen (San Diego,
California); 9E10 was from Covance (Princeton, New Jersey); 2D3 was from Calbiochem (San
Diego, California); 6H9 was a kind gift from Dr. Mary Telen at Duke University. Cells were
labeled with antibodies at room temperature unless otherwise stated: typically, about 107 cells
were washed twice in PBS with 0.1% bovine serum albumin (BSA) and incubated with primary
antibody for 30 minutes with gentle agitation. After two more washes, the cells were incubated
with secondary antibody for 30 minutes in the dark. The cells were then washed once more and
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suspended in PBS +0.1% BSA on ice for analysis. Microscopic Images were acquired on a
Nikon TE300 inverted microscope with a 60 X (oil, 1.4 NA) objective using a Cascade CCD
camera (Photometrics, Tuscon, AZ). Image acquisition was performed with Image Pro software
(Media Cybernetics, Silver Spring, MD). Flow cytometry experiments were performed on the
Becton-Dickinson (San Jose, CA) FACScan or FACSCalibur machines at the Flow Cytometry
Shared Facility in the School of Medicine, University of Pennsylvania.

Protein stripping and western blotting
Pelleted cells were stripped of displayed protein by gentle shaking with 1 mM DTT in 50 mM
Tris-HCl, pH 8, for 1 hour at 4°C in one-tenth the volume of the original culture (Watzele et al.,
1988). Digestion with enterokinase (New England Biolabs) was performed overnight at room
temperature in the same buffer, which was supplemented for this purpose with 50 mM NaCl and
2 mM CaCl2. Digestion with PNGase F closely followed the instructions of the manufacturer
(New England Biolabs). Thus, the sample was heated with denaturing buffer for 10 minutes at
90º C, followed by the addition of NP-40 and the enzyme. The mixture was incubated overnight
at 37ºC.

SDS-PAGE was performed using the XCell Surelock module (Invitrogen) and

NuPAGE gels with MES as the running buffer (Invitrogen). The sample was heated in loading
buffer (Invitrogen) with reducing agent, following the manufacturer’s directions. Anti-oxidant
was added to the running buffer as well. Following electrophoresis, protein was transferred to a
0.2 µm PVDF membrane (BIORAD, Hercules, CA) using the XCell II Blot Module (Invitrogen).
The membrane was blocked with 5% non-fat milk in TTBS (Tris-buffered saline with 1%
Tween 20) by shaking for 1 hour at room temperature or overnight at 4ºC, washed with TTBS
and incubated with primary antibody (9E10 against c-myc tag) in TTBS for 1 hour with gentle
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shaking. After repeated washing, the membrane was incubated with secondary antibody (goat
anti-mouse conjugated with alkaline phosphatase, Sigma, St Louis, Missouri) in TTBS for 30
minutes. The membrane was washed again and incubated with the alkaline phosphatase
substrate, NBT-BCIP (Sigma). Quantification of scanned images was performed with Image J
(NIH) after scanned blots were converted to 8-bit black-and-white images.

Thermal denaturation
Heat denaturation experiments were carried out on 40 µl aliquots of yeast suspension (about 107
cells) that were washed twice and then suspended in PBS with 0.1% BSA (Orr et al., 2003).
The suspension was transferred to a thin walled PCR tube and held at the desired temperature in
a Sprint thermal cycler (Hybaid International) for 20 minutes. The sequence in which the
different temperatures were reached was scrambled between replicate runs. (In time-variant
experiments, the duration of incubation in the cycler was controlled).

The tube was then

removed quickly from the cycler and cooled on ice for between 5 and 10 minutes after which the
yeast suspension was diluted into 1 ml ice-cold PBS/BSA . After all of the samples had been
heat-treated, labeling with primary and secondary antibodies for flow cytometric analysis was
carried out on ice .
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RESULTS
Yeast surface display of IgCD47
IgCD47 expression was induced on the surface of S cerevisiae (Fig. 1A) as a fusion with the
mating protein, Aga2p. The IgCD47 domain is flanked at the amino terminal by the epitope tag,
c-myc, and at the carboxyl end by the FLAG tag which is itself separated from Aga2p by a
flexible, (Gly4Ser)3 linker (Figure 1A). Aga2p is linked to Aga1p on the yeast the cell wall by a
pair of disulfide bonds, which can be readily reduced for purification and analysis of the yeast
displayed protein (Watzele et al., 1988; Boder and Wittrup, 1997).

Fluorescence microscopy of IgCD47-expressing yeast cells using the mAb 6H9 confirmed the
edge-bright surface display of the construct (Figure 1B). Although a fraction of the induced
population remained dark (white arrow, Figure 1B) and was therefore considered to be nonexpressing, all of the control wild-type or uninduced yeast remained dark when similarly probed.
The same immunofluorescence scheme was then used to quantitate relative expression levels by
flow cytometry (FC).

Immunostaining with B6H12, anti-FLAG, or 9E10, a c-myc antibody,

followed with R-phycoerythrin-conjugated secondary, showed two broad populations of
expressing and non-expressing cells (Figure 1C), as generally reported by others with yeast
display (Boder and Wittrup, 2000). Similar bimodal patterns were obtained with 6H9 and 2D3,
other CD47 mAbs (data not shown). The non-expressing fraction at lower fluorescence levels
represents less than 40% of total cell number, and the strong signals elicited by the anti-FLAG,
anti-c-myc, and many CD47 mAbs clearly suggest that full-length IgCD47 is expressed.

It

should be noted that B6H12 is conformationally sensitive (Rosales et al., 1992) and reportedly
blocks binding of CD47’s physiological ligand, signal regulating protein

(SIRP ), which
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makes B6H12 a reasonable, high affinity surrogate for SIRP (Seiffert et al., 1999), in contrast
to 2D3 which is reportedly a non-blocking antibody (Seiffert et al., 1999).

The fusion protein was dissociated from the yeast surface in 1 mM DTT with gentle shaking in
the cold for one hour. FC using 9E10 on DTT-treated cells showed a greatly diminished positive
peak (data not shown), consistent with liberation of the fusion protein. Subsequent cleavage of
the DTT-treated supernatant by EK was used to separate Aga2p from IgCD47, and an aliquot of
this reaction mixture was then denatured and treated with the endoglycosidase, PNGase F, to
cleave N-linked sugars from the asparagine. SDS-PAGE was performed on EK-treated protein
samples both before and after PNGase treatment; and immunoblotted with the c-myc mAb 9E10
(Figure 2A).

DTT-liberated protein is heterogeneous in molecular weight. Major species are glycosylated
isoforms of IgCD47, with the highest molecular weight diffuse bands in lane 2 likely to represent
hyper-mannosylated IgCD47. Such post-translational modification is common to many species
of yeast, and has motivated re-engineering of yeast glycosylation pathways in Pichia (Hamilton
et al., 2003), since it often interferes with desired function. Treatment with PNGase, however,
collapses the bands into single major band around 17 kDa, (the calculated molecular weight for
the amino acid sequence of IgCD47 flanked by the c-myc and FLAG epitopes is 16 kDa). The
molecular weight of O-glycosylated Aga2p is ca. 18 kDa, while it appears close to 23 kDa on
SDS-PAGE (Capellaro et al, 1991; Huang and Shusta 2005). Minor bands constituting less than
10% of the protein are likely to be degradation products resulting from excessive EK-treatment
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since they were not observed with an alternative cleavage construct employing tobacco etch
virus protease as the cleaving reagent in place of EK (data not shown).

Glycosylation mutants and expression levels
In order to explore the effect of glycosylation on expression and binding function, we
constructed and expressed a spectrum of glycosylation mutants of IgCD47. IgCD47 is predicted
to be N-glycosylated at five possible sites: N5, N16, N32, N55 and N93. Putative N-linked
glycosylation sites were disrupted by an asparagine to glutamine mutation at one or more desired
locations. The fusion protein has an additional N-linked glycosylation site near the C-terminus
of Aga2p.

When blots of protein released by DTT + EK treatment of yeast expressing wild-type,
N16/55/93Q ( 3), N16/32/55/93Q ( 4), and N5/16/32/55/93Q ( 5) IgCD47 mutants were
probed with 9E10, hypergylcosylated protein (bands at >80kDa) was observed (Figure 2). Bands
around 25, 20, and 17 kDa are displayed by the

3,

4, and

5 mutants, respectively.

Unglycosylated protein is evident with the 4 mutant and, of course, in the 5 mutant, although
higher molecular weight bands are present as well (see below). Strikingly, the Aga2p-wild-type
IgCD47 fusion seems to be most heavily hyperglycosylated since the bands at high MW are
stronger than they are for the other mutants. Figure 2B depicts intensity traces over the relevant
lanes, with the vertical hash mark denoting the median molecular weight in each case. As might
be expected, the median molecular weight shifts lower as N-linked glycosylation is progressively
reduced (Figure 2B). The hyperglycosylation in

3 and

4 must be contributed by N5, the

glycosylation site that the two have in common. A possible contribution from glycosylation at
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N32 in 3 is likely to be smaller than that from N5 since silencing this site (going from 3 to 4)
has a comparatively smaller effect on the hyperglycosylated bands than when going from wildtype to

3. The bands at 20 and 25 kDa (boxed) for

4 and

3 IgCD47 may reflect the

emergence of protein that is exclusively core-glycosylated. Unglycosylated protein can also be
seen in the 4 mutant. The multiple bands between 31 and 40 kDa for the 5 and 4 mutants
may reflect incomplete EK digestion of the fusion protein, as suggested by the appearance of
nearly identical bands in absence of EK digestion of the

4 mutant Aga2p-IgCD47 (data not

shown).

When treated with PNGase F, the recombinant IgCD47 band collapses to about 17 kDa in all
cases. The effect of the glycosidase on the 5 mutant – with no N-linked glycosylation sites –
was negligible, as expected. The relative proportion of the approximately 17 kDa protein
between PNGase F-treated and untreated 5 mutant (Figure 2A) was nearly 1:1. This same ratio
for the other constructs is virtually 1:0, which indicates that at least N5 is universally occupied,
based on the mutants studied.

With site-by-site removal of glycosylation, display of IgCD47 decreased, as quantified by FC
measurements of IgCD47 (Figure 3A and B). At saturating mAb levels (for wild-type), FC using
B6H12 showed that all five single mutants (N5Q, N16Q, N32Q, N55Q, N93Q) differed little
from wild-type in staining level: the ratio of B6H12 binding to mutant normalized with respect to
wild-type was 1.16 ± 0.20 in all cases (data not shown). Evidently, no single glycosylation site
modulates binding of this ligand-surrogate mAb. The triple mutant 3 (N16/55/93Q) showed a
decrease in immunostaining compared to wild-type, and for both 4 and 5 the signal was even
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lower. Assuming B6H12 is sensitive to IgCD47 conformation but 9E10 is not, the fidelity of
folded IgCD47 expression seems not to be undermined by loss of glycosylation (the intensity
ratio remains around 1). Thus the parallel decrease in staining intensity for both mAbs strongly
suggests overall loss of expression rather than epitope rearrangement. Not only is no single
glycosylation site needed for binding of B6H12, but neither is any of the tested combinations.

Thermal effects and glycosylation
The effect of mutations on thermal stability of yeast-displayed protein has been measured by
incubating recombinant yeast at selected temperatures and measuring the remnant binding of a
conformation-sensitive antibody to the protein (Esteban and Zhao, 2004; Orr et al , 2003; Shusta
et al, 2000). We used B6H12 as the antibody and wild-type and the 5 mutant as samples, since
they represent the extremes of glycosylation.

To determine an appropriate duration of

incubation, a preliminary experiment was run wherein wild-type was held isothermally at 55 °C
(Figure 3A) for different durations. The binding of the c-myc antibody 9E10 was found to be
relatively temperature invariant (suggesting that the scaffold was stable in this temperature
range) whereas the binding of B6H12 decreased with time of incubation, yielding a t1/2 of 20
minutes. The variable-temperature study therefore used incubation durations of 20 minutes.

Data obtained from this experiment in two independent replicates are shown in Figure 4B. The
error bars represent standard deviations and the fit was drawn with a simple two-state model. The
leveling-off at high temperature seen in the

5 case probably stems from a conflation of

expressor and non-expressor populations (see the reduced separation even at room temperature in
this mutant vis-à-vis wild-type in Figure 3A) of the two peaks. Notwithstanding the substantial
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change in glycosylation between wild-type and

5 (Figure 2) the temperature dependence of

B6H12 binding and thus conformational stability of the two samples seems very similar. The
temperature at which half the binding is retained (t1/2) is around 60 °C in each case.

Cysteine mutants and the core disulfide
The disulfide bond between a pair of core cysteine residues, usually about 50-70 amino acids
apart in primary sequence, is a defining feature of almost any extracellular Ig domain. In
IgCD47, Cys23 and Cys96 form a disulfide bond (Rebres et al., 2001; see Fig.1). A “free”
cysteine (Cys15) is believed to partner in a long-range disulfide bond with a cysteine presumed
to be located on an extracellular loop between transmembrane segments (Rebres et al., 2001),
but this latter cysteine is absent in the truncated construct expressed here. The role of the
cysteine residues was investigated by displaying the three single mutants: C15S, C23S and C96S
in the same fusion protein construct defined above.

Western blots were run on protein stripped as before from yeast expressing C23S and C96S
IgCD47 (Figure 5A). It is immediately apparent that the mutations lead to (1) a decrease in
hyperglycosylation with a shift toward lower molecular weight and (2) a weak band to appear
around 25 kDa, for both C96S and C23S. Upon treatment with PNGase F, the dominant band at
40 kDa resolves into a doublet above 31 kDa that is most likely due to incomplete
deglycosylation, whereas the band at 25 kDa is no longer seen. This observation leads us to
conclude that these bands are differentially glycosylated products with the 25 kDa band possibly
being core-glycosylated IgCD47. As with the glycosylation mutants, the median molecular
weight of the hyperglycosylation band is lower in the mutants compared to wild-type, suggesting

15
decreased hyperglycosylation in these cys mutants (Figure 5B). Removing the disulfide bond
thus decreases the average molecular weight of the added sugars, whether by limiting the length
of each chain or by sequestering some of the asparagines, suggesting that hyperglycosylation and
disulfide formation are coupled.

9E10 and B6H12 were used as before, to deconvolve the effects of the mutations on expression
level and structure, respectively (Figure 6A). The C15S mutant has staining intensities similar to
wild-type for both antibodies (Figure 6B), signifying that this mutation has little effect on
epitope and expression levels. When the core disulfide bond is broken by mutating either of the
two remaining cysteines to serine (C23S or C96S), the staining intensity with 9E10 and B6H12
falls off sharply, reaching disproportionately lower levels with B6H12 than with 9E10. The
C15S mutant has B6H12/9E10 staining intensity ratios of 0.8, which is within the range of noise
0.7-1.3 established as uncompromised expression of the glycosylation mutants (Figure 3). In
contrast, B6H12 binding falls off sharply relative to 9E10 to values of 0.3 and 0.1, for C23S and
C96S, respectively. The 9E10 intensity by itself falls only to around 30% of wild-type values
for C23S and C96S, whereas it remains around 1 for C15S (Figure 6B). We conclude that the
effect of breaking the core disulfide bond is to decrease the expression level by about one-third,
while also effectively abrogating B6H12 binding. In contrast, abolishing glycosylation ( 5) was
shown above to reduce surface expression by more than 90%, while still maintaining B6H12
reactivity.

Removal of N-glycosylation sites affects the level of expression of the protein, but not its ability
to fold. However, the effect on expression levels of removing either Cys23 or Cys96, which are
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likely to form a core disulfide bond, is symmetric, with expression levels dropping to 30% of
wild-type in either case. Whether this drop is mediated by the evident reduction in glycosylation
levels is not clear. Nonetheless, the effect of these two Cys mutations on folding of the B6H12
epitope appears asymmetric, with C96S destabilizing native-type folds somewhat more than
C23S.

DISCUSSION
Display of proteins on the cell wall of S. cerevisiae is a lively topic of research and has attracted
considerable attention since it combines ease of display with access to a broad ensemble of posttranslational modifications in an eukaryotic single cell host (Boder and Wittrup, 2000). There
are important issues to consider, however, with the expression of individual heterologous
proteins in this system. The N-linked glycosylation process in yeast differs considerably from
that in mammals in the sugars used, the types of linkage present and, most importantly, in the
number of residues attached (Gerngross, 2004; Hamilton et al., 2003). Hypermannosylation by
the yeast secretory pathway is a hurdle that must be overcome for functional expression of
heterologous proteins. CD47 is a ubiquitous cell-surface protein with a wide-ranging functional
repertoire (Mawby et al., 1994; Brown and Frazier, 2001; Mateo et al., 2002; Merdan et al.,
2003) that should be useful in future structure-function studies, provided the roles of
glycosylation and determinants of stability can first be carefully qualified.

Surface display of the extracellular Ig domain of human CD47, IgCD47, as a fusion protein with
Aga2p-Aga1p, a mating protein, was clearly accomplished here under the control of the GAL1
promoter. It binds common antibodies such as 2D3, 6H9 as well as the widely used SIRP blocking antibody, B6H12 (Figure 1).

Although a dozen or so proteins have been displayed on
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yeast, there is relatively little information on the specific effect of glycosylation on expression
and function. A lack of information on the occupancy of glycosylation sites in the native protein
generally complicates attempts to ascribe differences in activity seen in recombinant protein to
variant glycosylation.

Thus, possible hyperglycosylation was suggested as a cause for the

observed diminution in affinity seen with a surface-displayed epidermal growth factor receptor
(EGFR) (Cochran et al., 2004), which has 12 consensus N-linked glycosylation sites.

Several early steps in the process of N-linked glycosylation in the ER are conserved amongst
eukaryotes (Gerngross, 2004). The GlcNAc2Man9Glc3 unit added to an asparagine in the ER has
the three glucose units and a mannose trimmed when it leaves the ER en route to the Golgi.
Further processing of the sugars differs greatly amongst species and even between different
proteins in the same cell. In S. cerevisiae, some of the carbohydrate chains are poorly elaborated
with up to 14 mannoses, whereas some others are ‘hyperglycosylated” with the addition of 200300 mannoses (Conde et al., 2004). It should be noted that there are important differences
between glycosylation in the ER and the Golgi: ER glycosylation (“core glycosylation”)
proceeds co-translationally and is coeval with folding, enabling aspargines that will later be
buried to be modified with sugar residues, whereas hyperglycosylation in the Golgi takes place
on the fully-folded protein (Allen et al., 1995; Holst et al., 1996; Conde et al., 2004).
Hyperglycosylation in the Golgi can only occur with asparagines that are solvent-accessible in
the final structure.

There are reports that the NXT sequon is more likely to be glycosylated than the NXS sequon
(Gavel and von Heijne, 1990). Only N55 is part of an NXS sequon in IgCD47. Mellquist et al
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(1998) found that the amino acid immediately carboxy to the sequon also influences
glycosylation, but the modulation is much weaker for NXT than for NXS sequons in rabies virus
glycoprotein expressed in a cell-free system. The immediate environment of the sequon as well
as elements of tertiary structure would also be expected to modulate glycosylation (Kasturi et al.,
1995; Shakin-Eshleman et al., 1996).

Studying mutations in an NXS sequon in a model

exoglucanase in S. cerevisiae, Conde et al (2004) found that hyperglycosylation is favored when
X is a basic amino acid than an acidic one, or an aromatic amino acid such as tryptophan or
tyrosine but not phenylalanine. Only N16 has an acidic neighbor in IgCD47. The N-linked
glycosylation sequons in IgCD47 are compatible with these molecular determinants of
glycosylation/hyperglycosylation and one might therefore expect that the protein will be (hyper-)
glycosylated in S. cerevisiae.

Such is indeed the case. Abolishing the N-glycosylation sequon in stages with an N-to-Q
mutation, results in redistribution of glycosylation with a shift toward lower molecular weight, so
much so that core-glycosylated IgCD47 starts to appear in the 3 mutant, suggesting that N5 and
N32 are variably glycosylated.
N16,55,93Q triple mutation.

The

3,

4 and (of course) the

Considering the

5 mutants contain the

3 case first, the marked decrease in high

molecular weight bands suggests that N16, N55 and N93 are hyperglycosylated, although N16
may be less hyperglycosylated than the others since this sequon has an acidic amino acid in the
second position. Core- and hyperglycosylation at N5 and N32 would account for the remaining
bands seen. In 4, N32 is removed as a glycosylation site. The 3 and 4 lanes differ little at
high molecular weights suggesting that N32 may not be hyperglycosylated, but the band
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assigned to core glycosylation now decreases by around 5 kDa from 25 to 20 kDa, suggesting
that N32 has a core glycosylation unit of about 25 residues.

N5 is additionally lost as a glycosylation motif in the 5 mutant and the band at 20 kDa in 4
moves to a limiting value around 17 kDa, implying occupancy of about 15 core residues at N5.
The entire high molecular weight signal is absent for 5, suggesting that the faint bands seen in
the 3 and 4 cases arose from N5. In summary, our data indicate that N5, N16, N55 and N93
are hyperglycosylated. It is not clear whether N32 is hyperglycosylated. N32 and N5 seem to
have core glycosylation motifs of ~25 and ~15 mannose residues, respectively. Loss of N32
leads to anomalous mobility on the gel, but this is not exacerbated by the loss of glycosylation at
N5. This analysis assumes that the level of glycosylation at each sequon is independent of that at
other sequons but this remains to be proved. Loss of glycosylation may affect mobility on the
gel to a different extent than can be predicted by the resulting change in molecular weight.

The binding of a conformation-sensitive CD47 mAb, B6H12, parallels expression levels (as
measured by the mAb to the c-myc epitope tag, 9E10) in the case of the glycosylation mutants,
indicating that the expressed protein is folded correctly. The thermal profiles of the 5 mutant
and wild-type IgCD47 are very similar suggesting that their stabilities are likewise similar under
the conditions of the experiment. To set our data in perspective, swings in the t1/2 as large as 20
to 30 °C have been observed amongst mutants by Orr et al (2003) and Shusta et al., (2000).
Although the structural ramifications of the mutations engineered by these workers is not clear,
our mutations have been directed at reducing glycosylation and it is striking that removal of five
glycosylation sites results in negligible shift of the thermal profile. Wittrup and associates
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(1998) have described a model for secretion level by yeast with a quality control mechanism in
the endoplasmic reticulum: if the folding rate is not limiting, the relative stability of folded
versus unfolded forms (which are in pseudo-equilibrium) determines secretion level. The
reduction in the amount of protein displayed as glycosylation sites decrease could arise from a
kinetic or a thermodynamic bottleneck, or some combination of the two. Noting that (a) the
B6H12 epitope remains unaffected with loss of glycosylation (Figure 3B) and (b) the thermal
stability of the mutant protein appears to be similar to that of wild-type (Figure 4), it is clear that
progressively smaller amounts of “correctly folded” protein emerge on the surface as the number
of glycosylation sites decreases. Thus, the similar stability of the mutants argues for a kinetic
bottleneck brought about by limiting folding rates. In contrast to our results, a prior study found
no effect on display levels in response to mutation of N-linked glycosylation sites of a mutant
single-chain T cell receptor (Shusta et al, 2000). In this case, the mutant studied demonstrated an
unfolding transition midpoint of nearly 70°C, as opposed to the ~55°C midpoint observed for
CD47. These contrasting results suggest that the effects of glycosylation on display efficiency
might not apply to proteins of very high stability, although this hypothesis has not been tested.

Reports in the literature exploring the link between glycosylation and disulfide formation have
treated cells with a reducing agent to retain the reduced form of cysteine (Braakman et al., 1991;
Jamsa et al., 1994), an approach not feasible here where it would have resulted in cleavage of the
displayed protein from its anchor (Aga2p-S-S-Aga1P). This has generally led to an extension of
the duration spent by the protein in the ER. When CHO cells expressing t-PA (a protein richly
endowed with cysteines) were treated with DTT, reduced folding rates led to the glycosylation of
an asparagine that was not normally glycosylated (Allen et al., 1995). The authors suggest that

21
folding rates and glycosylation rates could compete, occasionally affording a normally buried
residue access to the glycosylation machinery. Upon DTT washout, the functionality of the
secreted protein was found to be unaffected. A recombinant carboxypeptidase in S. cerevisiae
was found to have a greater degree of glycosylation at newly-introduced N-linked glycosylation
sites with the details depending on folding conditions (Holst et al., 1996). Clearly, folding does
not precede glycosylation. In the present case, removal of each of the two cysteines decreases
the level of hyperglycosylation to the extent that a fraction of the protein is unglycosylated. The
effect is asymmetric between the two core cysteines. Disruption of the disulfide bond in an Ig
domain may thus hinder access to the glycosylating machinery and reduce the average molecular
weight of the carbohydrate chain.

The level of B6H12 binding does not reflect expression levels when the core cysteines (C23 and
C96) involved in the disulfide bond are mutated. The effect is asymmetric with the B6H12/9E10
intensity ratio decreasing far more for C96S than for C23S. The disulfide bond may serve to
bring together a patch of non-contiguous residues, thereby forming an epitope for B6H12, but the
epitope appears to partially survive the loss of the disulfide bond.

Evidently glycosylation, rather than the disulfide bond, plays a larger role in determining
whether an Ig domain can be robustly displayed on yeast. Proba et al. (1998) found that an scfv
fragment of an anti-HER2 antibody secreted into the periplasm of E. coli could fold correctly
even when the core disulfide cysteines were replaced by valine and alanine. Replacing cysteines
with serines had earlier been found to be more destabilizing than replacements with alanine or
valine in the case of bovine pancreatic trypsin inhibitor (Liu et al., 1996): although cysteine and
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serine differ only in the substitution of an –OH bond for the –SH bond, hydrogen-bonding does
not ameliorate the effect of burying polar groups in the interior of the molecule. The consensus,
corroborated by the present data, therefore seems to be that disulfide bonds are not indispensable
to the integrity of Ig domains and their display or secretion in prokaryotic or eukaryotic hosts. In
light of the anti-HER2 finding, it remains an open question whether other replacements of
cysteine in the present case would have retained functional integrity as reflected in an ability to
bind B6H12.
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FIGURE LEGENDS

Figure 1. (A) A schematic of the IgCD47-Aga2p fusion protein displayed on the surface of the
yeast cell. The molecular weights of Aga2p and unglycosylated IgCD47 (with the epitope tags)
are ~23 and 16 kDa, respectively. (B) Phase contrast (top) and immunofluorescence (bottom)
photographs of yeast cells after induction in galactose-containing selective medium. A CD47
monoclonal antibody, 6H9, was used to stain cells in the bottom panel followed by a polyclonal
TRITC-conjugated goat anti-mouse secondary. (C) Flow cytograms of induced yeast stained
with monoclonal anti c-myc , CD47 and anti-FLAG antibodies as indicated in each panel. The
secondary reagent was goat anti-mouse conjugated with R-phycoerythrin. Cells that do not
display the recombinant protein are evident in (B) and (C) and constitute typically 30-40% of the
total number.

Figure 2. (A) Western blots, under reducing conditions, of N-linked glycosylation mutants. (B)
Wild type and mutant IgCD47 was treated with enterokinase overnight, followed by PNGase F.
The contents of the lanes are as follows: marker, wild-type (wt), N16/55/93Q ( 3),
N16/32/55/93Q ( 4), N5/16/32/55/93Q ( 5) and marker. Blotted protein was probed with the
antibody, 9E10, to the c-myc epitope tag at the amino terminus of IgCD47.(B) Lane intensity
profiles for the recombinant proteins in panel (A) with the molecular weight at median intensity
indicated in each case by the vertical mark .
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Figure 3. (A) Flow cytograms of yeast displaying glycosylation mutants of IgCD47, stained
with the c-myc antibody, 9E10 (filled ) or the IgCD47 antibody, B6H12 (open), followed by R
phycoerythrin-conjugated goat anti-mouse secondary. The symbols denoting the samples in each
panel are described in the legend to Figure 3. (B) Normalized median intensities of the positive
peak (wild-type =100) measured with an antibody to c-myc (9E10, filled bar) and to CD47
(B6H12, open bar) for the different mutants. The error bar reflects the standard deviation of data
resulting from independent experiments. The B6H12/9E10 intensity ratio does not significantly
vary in the mutants reflecting a systematic drop in expression level, rather than epitope
rearrangement.

Figure 4. (A) Staining levels (normalized to a value of 1 at time zero) measured after different
intervals of time at 55ºC, using antibodies either to c-myc (9E10) or to CD47 (B6H12) with yeast
expressing the IgCD47 variants indicated. The 9E10 data were fit to a straight line, the other
lines shown are visual guides. (B) Staining levels of wild-type (closed) and 5 (open) IgCD47
with B6H12 after the yeast was heated for 20 minutes at the temperatures shown. Data are
normalized with respect to the staining intensity at 30 °C. Error bars represent the standard
deviation over two independent replicates. The line represents a two-state model fit to wild-type
data.

Figure 5. (A) Western blots of C96S IgCD47 or C23S IgCD47 under reducing conditions.
Protein stripped from the yeast surface with 1 mM DTT (see text) was subsequently treated with
enterokinase to cleave the IgCD47 from Aga2p and followed with the endoglycosidase, PNGase
F, to remove all N-linked sugars. Blotted protein was probed with the c-myc antibody, 9E10, to
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the epitope tag at the amino terminus of IgCD47. Lanes at extreme ends of the gels contained
molecular weight marker. (B) ) Lane intensity profiles for the recombinant proteins in panel (A)
with the molecular weight at median intensity indicated in each case by the vertical mark

Figure 6. (A) Flow cytograms of wild-type and cysteine-to-serine mutants stained with the cmyc antibody, 9E10 (filled ) or the IgCD47 antibody, B6H12 (open), followed by R
phycoerythrin-conjugated goat anti-mouse secondary. (B) Normalized median intensities of the
positive peak (wild-type =100) measured with an antibody to c-myc (9E10, filled bar) and to
CD47 (B6H12, open bar) for the different mutants.

